SCHEMBL24068636

SCHEMBL24068636

CCOC(=O)CCCCCCCN(CCCN=[N+]=[N-])C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.39
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CYP1A2 P05177 2/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
DNM1 Q05193 1/20 0.33
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
HDAC8 Q9BY41 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25756175 0.95 CA14 (0.39) CA14HDAC1HDAC2HDAC6CYP1A2
SCHEMBL16299776 0.83 CA14 (0.45) CA14HDAC1HDAC2HDAC6
SCHEMBL25756187 0.83 CA14 (0.43) CA14HDAC1HDAC2HDAC6ALDH1A1
SCHEMBL16299773 0.82 CA14 (0.44) CA14HDAC1HDAC2HDAC6
SCHEMBL15368955 0.82 CA14 (0.44) CA14HDAC1HDAC2HDAC6
SCHEMBL16299788 0.82 CA14 (0.44) CA14HDAC1HDAC2HDAC6
SCHEMBL20730040 0.81 CA14 (0.42) CA14HDAC1HDAC2HDAC6
SCHEMBL25755808 0.81 CA14 (0.34) CA14CYP4F2CYP4A11
SCHEMBL1272960 0.80 CA14 (0.49) CA14HDAC1HDAC2HDAC6CYP1A2
SCHEMBL25756173 0.80 CA14 (0.42) CA14HDAC1HDAC2HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20210369853-A1 TARGETED PROTEASE DEGRADATION PLATFORM EUBULUS BIOTHERAPEUTICS INC. (CN) 2021-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 CA14 2124/4885HDAC1 596/4885HDAC2 1263/4885
US-20210369853-A1 TARGETED PROTEASE DEGRADATION PLATFORM PSMB1, MDM2, XIAP CA14 1481/4885HDAC1 633/4885HDAC2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.